Drug
Levodopa Carbidopa Intestinal
Levodopa Carbidopa Intestinal: highest development phase Post-Market, developed by AbbVie. 1 trial record tracked on RxWires.
- Highest phase
- Post-Market
- Developer
- AbbVie
Trials
| Drug | Phase | Indication |
|---|---|---|
| Levodopa-carbidopa intestinal gel (LCIG) NCT00141518 | Post-Market | Advanced Idiopathic Parkinson's Disease |
Latest
No recent events.
Follow Levodopa Carbidopa Intestinal on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.